Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
VIR-7831 Suffers Setback In NIH Study
The DSMB of an NIAID study has recommended halting enrollment in the arm of hospitalized patients receiving VIR-7831 after data drew concerns about magnitude of benefit. • Source: Shutterstock
